Tempus AI Soars 10% on Q3 Beat and Raised Guidance as Oncology Sees “Accelerating Unit Growth”
Tempus AI (TEM) shares rose 10% after Q3 revenue beat expectations, growing 23% to $411.5M. Adjusted EBITDA increased to $25.6M. The company raised 2026 revenue guidance to $1.60B-$1.605B. Oncology test volume grew 32%, with MRD tests up 300%. Data and Applications revenue grew 33%, outpacing Diagnostics. Tempus competes with Natera (NTRA) and Guardant Health (GH).
How this was made
The 30-second read
Why it matters
The combination of a Q3 revenue beat, raised 2026 revenue guidance, and explicit gross margin expansion provides a concrete earnings-power update, while competitive comparisons to Natera and Guardant frame how durable Tempus’s oncology momentum may be.
Market read
Traders can reassess near-term expectations for EBITDA delivery and margin sustainability after the guidance raise and margin beat.
What to watch
The margin story depends on sustaining Data and Applications growth and licensing momentum; execution risk around reaching the $65M adjusted EBITDA target in Q4 is a key swing factor.
Background
Tempus AI is positioning its oncology growth around MRD test volume acceleration and a higher-margin data and licensing business.
Ticker impact
Tempus AI reported Q3 revenue of $411.5M, raised 2026 revenue guidance, and expanded margins as Data and Applications gross margin rose to 71.5%.
Likely upward bias as the market prices in sustained margin gains needed to reach the $65M adjusted EBITDA target.
The article’s primary new catalysts are the Q3 beat, guidance raise, and explicit margin drivers (data mix and gross margin), which directly affect near-term earnings power and valuation expectations.
The article compares Tempus’s MRD growth to Natera’s Signatera, noting Natera added 34,000 clinical MRD tests in Q2.
Likely limited downside or volatility, as the article also highlights Natera’s MRD test growth as still strong.
Natera is mentioned mainly for comparison, not as the source of a new company-specific disclosure in this article.
The article cites Guardant’s oncology test volume growth of 63% in Q2 and expectations of about 50% for the year.
Neutral-to-slightly negative bias only if the market interprets Tempus’s acceleration as share capture; otherwise limited impact.
Guardant is referenced for relative growth metrics, not a fresh catalyst or disclosure.
Market effects
Reinforces the oncology diagnostics and data-licensing model narrative, highlighting that data mix can drive margin expansion across the segment.
Primarily US-listed biotech/health-tech sentiment, with read-through to oncology testing peers.
Limited direct global macro linkage; relevant mainly to global oncology diagnostics investors tracking growth and margin structure.
Counterpoint
The article itself flags valuation risk: the stock trades above its one-year average on forward sales, so any margin deceleration could quickly reverse the post-beat optimism.
Key entities
- companyTempus AI
Reported Q3 beat, raised 2026 revenue guidance, and showed margin expansion driven by Data and Applications.
- companyNatera
Used as a competitive benchmark for MRD test growth (Signatera) in the article.
- companyGuardant Health
Used as a competitive benchmark for oncology test volume growth in the article.
- companyBristol Myers Squibb
Mentioned as a licensing customer for Tempus oncology data (licensing bookings above $550M YTD).
